# A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

> **NCT07010497** · PHASE2 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 33 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** irpagratinib

## Key facts

- **NCT ID:** NCT07010497
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010497, "A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07010497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*